← All Moonlake Immunotherapeutics filings

Moonlake Immunotherapeutics 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MLTX
Moonlake Immunotherapeutics
10-K: MoonLake Immunotherapeutics Advances SLK Pipeline
MoonLake Immunotherapeutics' 2025 annual report details significant clinical progress for Sonelokimab across multiple inflammatory diseases, despite increased net losses.
NASDAQ
MLTX
Moonlake Immunotherapeutics
10-K: MoonLake Immunotherapeutics Reports Full Year 2024 Results, Highlights Progress of SLK Clinical Programs
MoonLake Immunotherapeutics' 10-K filing details the company's financial results for 2024 and provides an update on the clinical development of their lead asset, Sonelokimab (SLK), across multiple inflammatory disease indications.
NASDAQ
MLTX
Moonlake Immunotherapeutics
10-K/A: MoonLake Immunotherapeutics Files Amended 10-K, Reaffirming Financial Accuracy and Control
MoonLake Immunotherapeutics has filed an amendment to its annual report on Form 10-K, correcting a minor error in certifications and reaffirming the accuracy of its financial statements and internal controls.
NASDAQ
MLTX
Moonlake Immunotherapeutics
10-K: MoonLake Immunotherapeutics Files 10-K, Details Clinical Progress and Financial Position
MoonLake Immunotherapeutics' 10-K filing highlights positive clinical trial results for Sonelokimab (SLK) and provides an overview of the company's financial status and future plans.